Evidence map›Paper›PMID 22116688›Full record

ArticleClinical and vaccine immunology : CVI2012

Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays.

Aditi Kapasi, Bruce D Meade, Brian Plikaytis, Lucia Pawloski, Monte D Martin, Sandra Yoder, Michael T Rock, Séverine Coddens, Valérie Haezebroeck, Françoise Fievet-Groyne and 6 more

Open access · diamondAbstract readComparative StudyEvaluation StudyMulticenter Study
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens.Biologicals : journal of the International Association of Biological Standardization · 2019
    Article
  9. Observational
  10. Evaluation of Commercial Assays for Single-Point Diagnosis of Pertussis in the US.Journal of the Pediatric Infectious Diseases Society · 2017
    Article
  11. Laboratory Diagnosis of Pertussis.Clinical microbiology reviews · 2015
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Aditi KapasiDivision of Bacterial Diseases, NCIRD, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Bruce D Meade
Brian Plikaytis
Lucia Pawloski
Monte D Martin
Sandra Yoder
Michael T Rock
Séverine Coddens
Valérie Haezebroeck
Françoise Fievet-Groyne
Garvin Bixler
Charles Jones
Stephen Hildreth
Kathryn M Edwards
Nancy E Messonnier
Maria L Tondella
National Center for Immunization and Respiratory Diseases · USGlaxoSmithKline (Belgium) · BESanofi (United States) · USVanderbilt University Medical Center · USCenters for Disease Control and Prevention · USHeat Biologics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In an effort to improve the reliability and reproducibility of serological assays for Bordetella pertussis, a collaborative study was conducted to compare four different sources of pertussis toxin (PT) as coating antigens in the immunoglobulin G (IgG) anti-PT enzyme-linked immunosorbent assay (ELISA). Four sources of PT were used as coating antigens in the IgG anti-PT ELISA in four different testing laboratories (labs A to D) to determine whether the different antigen preparations and different laboratories influenced assay results. A panel of 60 sera consisting of deidentified human specimens from previous vaccination trials of healthy adults and infants and clinical specimens from outbreak settings was tested. In the four laboratories, each sample was tested three times with the four PT antigens according to the standard coating optimization and IgG anti-PT ELISA testing procedures used in that laboratory. Differences among the antigens, as well as intra- and interlaboratory variability, were evaluated. Excellent agreement was observed with the test panel results among the four antigens within each laboratory. Concordance correlation coefficient (r(c)) measurements among the different antigens ranged from 0.99, 0.99 to 1.00, 1.00, and 0.97 to 1.00 for labs A to D, respectively. The comparisons between pairs of laboratories also indicated a high degree of concordance for each PT preparation, with r(c) measurements between 0.90 and 0.98, 0.93 and 0.99, 0.92 and 0.98, and 0.93 and 0.99 for antigens 1 to 4, respectively. Relatively minor differences in results were observed among laboratories or among antigens, suggesting that the four PT antigens are quite similar and could be considered for acceptance in harmonized immunoassays used for serodiagnosis or vaccine evaluation.

Indexed as

Pertussis ToxinAdultAntibodies, BacterialBordetella pertussisChild, PreschoolClinical Laboratory TechniquesEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin GInfantReproducibility of ResultsWhooping CoughAntibodies, BacterialImmunoglobulin GPertussis Toxin

Identifiers

PMID22116688
PMCPMC3255951
OpenAlexW2123219792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.